Results 131 to 140 of about 18,344 (221)

Fluticasone- vs Budesonide-Based Dual Therapy for COPD.

JAMA Netw Open
Feldman WB, Ambati VL, Suissa S, Kesselheim AS, Avorn J, Schneeweiss S, Wang SV.   +6 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study. [PDF]

J Asthma Allergy
Gessner C, Russell REK, Greulich T, Lommatzsch M, Suppli Ulrik C, Pohl W, Plaza V, Bourdin A, Kupczyk M, Braido F, Piraino A, Scaffidi-Argentina U, Bogoevska V, Trinkmann F, TriMaximize Core team, TriMaximize Core team, Akyildiz B, Fritz C, Grickschat V, Hahn A, Baumeister S, Richards J, Kisiel J, Krogh N.   +23 more
europepmc   +1 more source

Rethinking asthma therapy, part 1: transdermal delivery of β₂-agonists. [PDF]

J Pharm Pharm Sci
Correa J, Brogden NK.
europepmc   +1 more source

Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study. [PDF]

Int J Clin Pharm
Dong YH, Pan SW, Chen MC, Chen CY, Tsai NH, Kumamaru H.   +5 more
europepmc   +1 more source

Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma.

JAMA Netw Open
Pham T, Barker AR, Eisenstein SA, Jost E, Volerman A, Chauhan K, Brownson RC, McBride T, Huffman MD, Sumino K, Gerald LB, Castro M, Dixon AE, Krings JG.   +13 more
europepmc   +1 more source

Effectiveness and Safety of Glycopyrronium-Formoterol-Budesonide Triple Therapy in Chronic Obstructive Pulmonary Disease (AIR-FORCE): An Open-Label Multi-Centric Phase 4 Study. [PDF]

Adv Respir Med
Nath AR, Kumar A, Bhate AS, Mehrotra B, Rai DK, Barge VK, Bhojwani D, Bhagat S, Bhushan S, Patil S, Barkate H.   +10 more
europepmc   +1 more source

Implementation of a stepped anti-inflammatory reliever therapy intervention with budesonide-formoterol 160/4·5 mcg by Turbuhaler versus usual care for adults presenting during exacerbations of obstructive lung disease suggestive of asthma or chronic obstructive pulmonary disease in a resource-limited setting: an open-label, cluster randomised trial. [PDF]

EClinicalMedicine
Fox GJ, Chau NQ, Yen PN, Van Giap V, Li Q, Jan S, Huang E, Negin J, Anh NT, Reddel H, Marks GB.   +10 more
europepmc   +1 more source

Prescriber adherence to asthma treatment guidelines and its impact on symptom control in Ethiopia: a mixed-methods study. [PDF]

Ther Adv Respir Dis
Assefa AN, Alemu MA, Tadesse TY, Aklog AT, Tarekegn GY, Moges TA, Dagnew SB.   +6 more
europepmc   +1 more source

In silico Lung Deposition Profiles of Three Single-Inhaler Triple Therapies in Patients with COPD Using Functional Respiratory Imaging [Letter]. [PDF]

Int J Chron Obstruct Pulmon Dis
Zambelli E, Warner L, Richards J, Malone R, Piraino A.   +4 more
europepmc   +1 more source

Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate After Dual and Triple Therapy in Spain: A Sub-Study of the ORESTES Study. [PDF]

Pulm Ther
Figueira-Gonçalves JM, Alcázar-Navarrete B, Casitas-Mateo R, González J, Gotera-Rivera CM, Herrejón-Silvestre A, Margallo-Iribarnegaray J, Martín-Lana M, Pallarés-Sanmartín A, Pascual-Guardia S, Saura-Vinuesa A, Corregidor-García C, Fitas E, Sánchez-Covisa J.   +13 more
europepmc   +1 more source